Trial Information

Summary: MK0249 for the Symptomatic Treatment of Alzheimer's Disease

A multi-center, randomized, double-blind, placebo control, parallel-group trial to evaluate the safety and efficacy of MK-0249 for the symptomatic treatment of Alzheimer’s Disease

Patient Inclusion Criteria:

• Male or females age 55 years or older
• Mild-to-moderate Alzheimer's Disease, with MMSE between 18 and 26, and have a reliable informant/caregiver to accompany patient to all visits
• If taking Alzheimer's Disease treatments, patients must be on a Stable Dose for at least 2 months

Patient Exclusion Criteria:

• Patient is living in a nursing home or skilled nursing facility.
• Patient has poorly-controlled hypertension
• Patient has past or current history of significant cardiovascular disorders, active major depressive disorder, gastroesophageal reflux disease (GERD), or clinically significant sleep disorder

If you would like to learn more about participating in this study, please send an e-mail message using the form below.